United States securities and exchange commission logo





                            June 25, 2020

       Snehal Patel
       Chief Executive Officer
       Greenwich LifeSciences, Inc.
       3992 Bluebonnet Dr, Building 14
       Stafford, TX 77477

                                                        Re: Greenwich
LifeSciences, Inc.
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed June 23, 2020
                                                            File No. 333-238829

       Dear Mr. Patel:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 1 to Registration Statement on Form S-1

       Calculation Of Registration Fee

   1.                                                   It appears that you
have based your calculations for the Proposed Maximum Aggregate
                                                        Offering Price on a per
share price of $8.00, which represents the midpoint of your
                                                        offering range between
$7.50 and $8.50 per share. Please revise to use the top of your
                                                        offering price range as
the basis for your calculations. Please also revise the Amount
                                                        of Registration Fee
column and pay any additional fee, as necessary. Refer to Rule 457(o)
                                                        of the Securities Act
for guidance.

       Exhibit 3.6. Form of Second Amended and Restated Bylaws, to be effective
immediately prior to
       the closing of this offering
       Article 11. Exclusive Forum
 Snehal Patel
Greenwich LifeSciences, Inc.
June 25, 2020
Page 2

2.    Please revise Article 11 of your Bylaws to clearly state that the
provision (i) does not
      apply to federal securities law claims or (ii) applies only to state law
claims, as
      applicable. Alternately, please provide reasonable assurance that you
will make future
      investors aware of the provision's limited applicability by including
such disclosure in
      your future Exchange Act reports. In this regard, we note the risk factor
you have
      included on page 42 of your Prospectus, Our Amended and Restated Bylaws
to be effective
      upon completion of this offering provides that the Court of Chancery of
the State of
      Delaware will be the sole and exclusive forum for substantially all
disputes....
       You may contact Jenn Do at 202-551-3743 or Terence O'Brien at
202-551-3355 if you
have questions regarding comments on the financial statements and related
matters. Please
contact David Gessert at 202-551-2326 or Michael Clampitt at 202-551-3434 with
any other
questions.



                                                         Sincerely,
FirstName LastNameSnehal Patel
                                                         Division of
Corporation Finance
Comapany NameGreenwich LifeSciences, Inc.
                                                         Office of Life
Sciences
June 25, 2020 Page 2
cc:       Jeffrey J. Fessler, Esq.
FirstName LastName